President Donald Trump speaks with reporters as he walks from Marine One after arriving on the South Lawn of the White House, Tuesday, Sept. 30, 2025, in Washington. (AP Photo/Alex Brandon)

...

Jenna SundelGabe Whisnant

By Jenna Sundel and Gabe Whisnant

0

Share

Newsweek is a Trust Project member

See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.


The Trump administration will launch a website that allows consumers to purchase prescription drugs directly rather than through insurance, press secretary Karoline Leavitt confirmed on Tuesday.

Leavitt said on X that the White House will also announce that Pfizer will reduce prices on several medications in the United States. The Wall Street Journal was the first to report the news.

Why It Matters

The announcements come after Trump’s deadline for drug companies to lower prices for Americans expired Monday. Some pharmaceutical trade groups said they are investing in U.S. manufacturing and addressing causes of high costs, though it is unclear if those steps meet Trump’s demands.

Read More on News

While the Biden administration negotiated with drugmakers to lower costs for some of Medicare’s most expensive drugs, White House spokesperson Kush Desai argued that Trump is the one taking action.

“President Trump is doing more to lower health care costs than anyone else in Washington, D.C.,” Desai said in a statement to the Associated Press.

President Donald Trump speaks with reporters on the South Lawn of the White House on September 30, 2025. (AP Photo/Alex Brandon)

...

White House Launches 'TrumpRx': What Is It?

TrumpRx would allow people to pay cash for certain drugs directly from a government website at a reduced price negotiated by the government, The Wall Street Journal reported. It is unclear whether the website will be helpful for Americans covered by private insurance, Medicare or Medicaid.

Leavitt shared a photo of a poster on X that states TrumpRx will reduce the cost of post-menopausal osteoporosis medication Duavee by 85 percent, dermatitis medication Eucrisa by 80 percent, migraine medication Zavzpret by 50 percent, and rheumatoid arthritis medication Xeljanz by 40 percent.

The program will cover medicine for diseases affecting 100 million Americans, according to the poster.

However, NPR reported that an anonymous government official said that the discounts would only apply to people paying out of pocket, and because they are tied to the drugs’ high list prices, the reduced rates might still leave many patients paying more than they would through their insurance.

The American Journal of Managed Care reported that the initiative is expected to face legal challenges and could prove difficult to implement, with industry analysts warning that the plan risks acting as a blunt instrument rather than a workable solution. Ali Pashazadeh, CEO of Treehill Partners, told AJMC, “I understand the logic of doing it… the question is how it’s implemented, and also the timing of implementation.”

What Was Trump's Deadline for Drug Companies to Lower Medication Costs?

On July 31, Trump gave 17 pharmaceutical companies, including Pfizer, 60 days to bring down drug costs. The deadline was Monday.

Trump announced on Tuesday that Pfizer would only charge Medicaid what he called “Most Favored Nation” prices for its pharmaceutical drugs.

"It's going to have a huge impact on bringing Medicaid costs down," Trump said.

What People Are Saying

President Donald Trump told reporters: "Our prices are coming down massively."

White House press secretary Karoline Leavitt, on X: "In July, President Trump sent powerful letters to pharmaceutical companies outlining the steps they needed to take to bring down the prices of prescription drugs. Today, Pfizer answered and agreed to lower prices for the American people. Presidential leadership on full display."

But critics argue the impact will be limited.

Ameet Sarpatwari, an assistant professor at Harvard Medical School, told NPR: “I think it’s more underwhelming than what the president is touting. I think it’s more window dressing than the transformational sort of reforms that are needed to really provide relief to Americans struggling with high prices.”

The American Journal of Managed Care also highlighted concerns from analysts about the viability of the plan. Neal Masia, CEO of EntityRisk, described the approach as a “blunt instrument,” while Ali Pashazadeh, CEO of Treehill Partners, told AJMC, “I understand the logic of doing it… the question is how it’s implemented, and also the timing of implementation.”

What Happens Next

The president also stated that Pfizer would invest $70 billion in domestic manufacturing facilities; however, it’s unclear what the timeline for this investment would be or how it compares to previous investments.

NPR reported that the administration has not detailed how discounts will be calculated or whether the program will reduce overall drug spending. Analysts warned that consumers with insurance may continue to pay less at the pharmacy counter than through the TrumpRx website, raising questions about the program’s broader usefulness.

Meanwhile, AJMC noted that the Most Favored Nation order underpinning TrumpRx is likely to face legal challenges, as a similar effort during Trump’s first term was blocked in court. Experts caution that without careful implementation, the plan could disrupt innovation while failing to meaningfully change what most Americans pay.

This article includes reporting by the Associated Press.

Do you have a story that Newsweek should be covering? Do you have any questions about this story? Contact LiveNews@newsweek.com.

Update 9/30/25, 1:15 p.m. ET: This article was updated with additional information.

Update 09/30/25 8:38 p.m. ET: This article was updated with additional information.

View 0 Comments

Request Reprint & Licensing

Submit Correction

View Editorial & AI Guidelines